AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) insider Vinayak Doraiswamy sold 5,000 shares of the business's stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $29.83, for a total transaction of $149,150.00. Following the transaction, the insider owned 96,875 shares in the company, valued at approximately $2,889,781.25. The trade was a 4.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
AtriCure Stock Up 2.0%
NASDAQ ATRC opened at $30.44 on Tuesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.99 and a current ratio of 3.96. The firm has a 50-day simple moving average of $35.05 and a 200 day simple moving average of $36.05. AtriCure, Inc. has a twelve month low of $28.29 and a twelve month high of $43.18. The stock has a market cap of $1.52 billion, a PE ratio of -126.83 and a beta of 1.42.
AtriCure (NASDAQ:ATRC - Get Free Report) last issued its quarterly earnings results on Tuesday, February 17th. The medical device company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.10. The firm had revenue of $140.50 million for the quarter, compared to analyst estimates of $140.50 million. AtriCure had a negative return on equity of 1.15% and a negative net margin of 2.14%.The company's quarterly revenue was up 13.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.33) earnings per share. On average, research analysts forecast that AtriCure, Inc. will post -0.6 EPS for the current year.
Analyst Ratings Changes
A number of brokerages recently commented on ATRC. Citigroup restated an "outperform" rating on shares of AtriCure in a research note on Wednesday, February 18th. Weiss Ratings reiterated a "sell (d-)" rating on shares of AtriCure in a research note on Wednesday, January 21st. JPMorgan Chase & Co. lowered shares of AtriCure from an "overweight" rating to a "neutral" rating and set a $36.00 price target on the stock. in a report on Wednesday, February 11th. Zacks Research cut shares of AtriCure from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, February 18th. Finally, Canaccord Genuity Group reduced their price objective on shares of AtriCure from $64.00 to $53.00 and set a "buy" rating for the company in a report on Wednesday, February 18th. Six research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, AtriCure currently has a consensus rating of "Moderate Buy" and a consensus price target of $48.43.
Read Our Latest Stock Report on AtriCure
Institutional Trading of AtriCure
A number of large investors have recently bought and sold shares of the stock. Invesco Ltd. raised its stake in AtriCure by 7.9% during the fourth quarter. Invesco Ltd. now owns 74,435 shares of the medical device company's stock worth $2,945,000 after acquiring an additional 5,462 shares in the last quarter. Mackenzie Financial Corp boosted its stake in shares of AtriCure by 5.3% in the 4th quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company's stock valued at $545,000 after purchasing an additional 683 shares in the last quarter. XTX Topco Ltd grew its holdings in shares of AtriCure by 88.0% in the 4th quarter. XTX Topco Ltd now owns 11,069 shares of the medical device company's stock worth $438,000 after purchasing an additional 5,182 shares during the last quarter. Susquehanna Portfolio Strategies LLC bought a new stake in shares of AtriCure in the 4th quarter worth about $3,415,000. Finally, Engineers Gate Manager LP increased its position in shares of AtriCure by 104.2% during the 4th quarter. Engineers Gate Manager LP now owns 58,479 shares of the medical device company's stock worth $2,313,000 after purchasing an additional 29,839 shares in the last quarter. 99.11% of the stock is currently owned by institutional investors.
About AtriCure
(
Get Free Report)
AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.
The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
